Propanc Biopharma, Inc.
- PPCB
- NASDAQ
- Biotechnology
- Oncology Biotech (Cancer Therapeutics)
- Clinical-Stage Biopharma
$0.32
Today −7.31%Quote Oct 19, 2026, 08:00 PM UTC
−48.03%over the last month
Max drawdown −51.3%From 1-month high −51.3%3 months −77.0%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Propanc Biopharma
Propanc Biopharma, Inc. (PPCB) is an Australian biopharmaceutical firm dedicated to developing innovative treatments for various cancers, with a particular focus on pancreatic, ovarian, and colorectal malignancies. The company's leading therapeutic candidate, PRP, is a unique formulation currently in the preclinical stage of development.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
2
Founded
2007
Market value
$2.0M
Quote Oct 19
Floor
$0.28
11.2% below price
Resistance
$0.39
21.6% above price
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about PPCBPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free